|

Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura

RECRUITINGN/ASponsored by Sohag University
Actively Recruiting
PhaseN/A
SponsorSohag University
Started2025-07-14
Est. completion2026-01-20
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07093606

Summary

this study amis to assess the incidence and severity of liver dysfunction in ITP patients receiving eltrombopag.

Eligibility

Age: 18 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria Adult patients (≥18 years) diagnosed with primary ITP. Receiving eltrombopag as part of their treatment. Baseline liver function tests (LFTs) within normal limits. Patients with diabetes Patients without diabetes Patients with fatty liver Patients without fatty liver

Exclusion Criteria:

Pre-existing liver disease (e.g., hepatitis, cirrhosis, NAFLD). Concurrent use of hepatotoxic drugs. Patients lost to follow-up.

Conditions2

ITP - Immune ThrombocytopeniaLiver Disease

Browse More Trials

Liver Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.